Presidential risk assessment
This article was originally published in The Gray Sheet
Office of Management and Budget official John Graham endeavors to bring in outside expertise in risk assessment as a part of the administration's performance-based management system. Graham, OMB's administrator of the Office of Information and Regulatory Affairs, "is a leading expert in the nation on decision sciences in risk assessment and cost benefit analysis," according to OMB's Paul Noe at the Washington Legal Foundation, June 4. OIRA "is traditionally an office dominated by economists and [Graham] is trying to expand and deepen our expertise." Risk assessment has taken on more emphasis since the appointment of Acting FDA Director Lester Crawford, who views his role to be "risk manager" (1"The Gray Sheet" April 22, 2002, p. 5)...
You may also be interested in...
Ties to an FDA-regulated industry should not preclude a candidate's nomination to the agency's top position, Sen. Orrin Hatch (R-Utah) asserted April 16 at the Food & Drug Law Institute Educational Conference in Washington, D.C
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.